KR20070117547A - 뇌암 치료방법 - Google Patents
뇌암 치료방법 Download PDFInfo
- Publication number
- KR20070117547A KR20070117547A KR1020077017960A KR20077017960A KR20070117547A KR 20070117547 A KR20070117547 A KR 20070117547A KR 1020077017960 A KR1020077017960 A KR 1020077017960A KR 20077017960 A KR20077017960 A KR 20077017960A KR 20070117547 A KR20070117547 A KR 20070117547A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- quinazolin
- alkyl
- phenyl
- amine
- Prior art date
Links
- 0 Cc1c(*)c(*)c(*)c(*)c1C Chemical compound Cc1c(*)c(*)c(*)c(*)c1C 0.000 description 3
- NOIWFFVYMNYOGJ-UHFFFAOYSA-N CC(C1)C=CC2(C)C1=NC(N(C)C)=NC2N(C)C(CC1)=CCC1OC Chemical compound CC(C1)C=CC2(C)C1=NC(N(C)C)=NC2N(C)C(CC1)=CCC1OC NOIWFFVYMNYOGJ-UHFFFAOYSA-N 0.000 description 1
- AKFHIQXDZMGKMN-UHFFFAOYSA-N CN(c(cc1)ccc1OC)c1c(cccc2)c2ncc1 Chemical compound CN(c(cc1)ccc1OC)c1c(cccc2)c2ncc1 AKFHIQXDZMGKMN-UHFFFAOYSA-N 0.000 description 1
- YWAGOXUERHPQNE-UHFFFAOYSA-N Cc1nc(cccc2)c2c(N(C)c(cc2)cnc2N(C)C)n1 Chemical compound Cc1nc(cccc2)c2c(N(C)c(cc2)cnc2N(C)C)n1 YWAGOXUERHPQNE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64126305P | 2005-01-03 | 2005-01-03 | |
| US60/641,263 | 2005-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070117547A true KR20070117547A (ko) | 2007-12-12 |
Family
ID=36648123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077017960A KR20070117547A (ko) | 2005-01-03 | 2006-01-03 | 뇌암 치료방법 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1833511A4 (fr) |
| JP (1) | JP2008526776A (fr) |
| KR (1) | KR20070117547A (fr) |
| CN (1) | CN101287369A (fr) |
| AU (1) | AU2006204052A1 (fr) |
| CA (1) | CA2592971A1 (fr) |
| WO (1) | WO2006074187A2 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005048948A2 (fr) | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Derives d'uree en tant que modulateurs de la kinase |
| WO2008124824A1 (fr) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Doses et méthodes de traitement du cancer |
| EP2144504A4 (fr) * | 2007-04-10 | 2012-10-03 | Myrexis Inc | Méthode de traitement du cancer du cerveau |
| FR2932180B1 (fr) * | 2008-06-04 | 2012-08-10 | Centre Nat Rech Scient | Dihydro iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de la polymerisation de la tubuline |
| AR085817A1 (es) | 2011-03-15 | 2013-10-30 | Chiesi Farma Spa | Derivados de isoxazolidina |
| RU2013141933A (ru) | 2011-03-15 | 2015-03-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные изоксазолидина |
| FR3019819B1 (fr) | 2014-04-09 | 2018-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Composes cytotoxiques inhibiteurs de la polymerisation de la tubuline |
| EP3601267A1 (fr) | 2017-03-21 | 2020-02-05 | Bayer Pharma Aktiengesellschaft | 2-méthyl-quinazolines |
| EP3781565A1 (fr) | 2018-04-18 | 2021-02-24 | Bayer Pharma Aktiengesellschaft | 2-méthyl-aza-quinazolines |
| FR3080620B1 (fr) * | 2018-04-27 | 2021-11-12 | Univ Paris Sud | Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL88507A (en) * | 1987-12-03 | 1993-02-21 | Smithkline Beckman Intercredit | 2,4-diaminoquinazolines, process for their preparation and pharmaceutical compositions comprising them |
| ATE121735T1 (de) * | 1991-02-20 | 1995-05-15 | Pfizer | 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen. |
| EP0954315A2 (fr) * | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Utilisation de derives de la quinazoline pour la fabrication d'un medicament destine au traitement de troubles cutanes hyperproliferatifs |
| EP1082311A1 (fr) * | 1998-05-28 | 2001-03-14 | Parker Hughes Institute | Utilisation des quinazolines pour le traitement de tumeurs cerebrales |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| WO2005003100A2 (fr) * | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Composes et leur utilisation therapeutique |
| CN101031551A (zh) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂 |
| CA2592900A1 (fr) * | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Composes et utilisation therapeutique associee |
-
2006
- 2006-01-03 EP EP06717342A patent/EP1833511A4/fr not_active Withdrawn
- 2006-01-03 AU AU2006204052A patent/AU2006204052A1/en not_active Abandoned
- 2006-01-03 WO PCT/US2006/000122 patent/WO2006074187A2/fr active Application Filing
- 2006-01-03 CA CA002592971A patent/CA2592971A1/fr not_active Abandoned
- 2006-01-03 CN CNA2006800025252A patent/CN101287369A/zh active Pending
- 2006-01-03 JP JP2007549710A patent/JP2008526776A/ja active Pending
- 2006-01-03 KR KR1020077017960A patent/KR20070117547A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006074187A3 (fr) | 2008-01-10 |
| AU2006204052A1 (en) | 2006-07-13 |
| EP1833511A4 (fr) | 2011-01-19 |
| CN101287369A (zh) | 2008-10-15 |
| EP1833511A2 (fr) | 2007-09-19 |
| JP2008526776A (ja) | 2008-07-24 |
| WO2006074187A2 (fr) | 2006-07-13 |
| CA2592971A1 (fr) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7989462B2 (en) | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| JP5129957B2 (ja) | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン | |
| US8258145B2 (en) | Method of treating brain cancer | |
| US8309562B2 (en) | Compounds and therapeutical use thereof | |
| KR20070117547A (ko) | 뇌암 치료방법 | |
| US20070099877A1 (en) | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| US20070213305A1 (en) | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| WO2008057402A2 (fr) | N-aryl-isoxazolopyrimidin-4-amines et composés associés servant d'activateurs de caspases et d'inducteurs d'apoptose et leur utilisation | |
| US7842805B2 (en) | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof | |
| US20080113946A1 (en) | N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | |
| US20080096848A1 (en) | Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as Activators of Caspases and Inducers of Apoptosis | |
| US20050014759A1 (en) | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | |
| US20070244114A1 (en) | Compounds and therapeutical use thereof | |
| WO2009094205A2 (fr) | 3-aryl-6-aryl-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadazines et analogues en tant qu'activateurs de caspases et inducteurs d'apoptose, et leur utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |